Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DimerixASX:DXB +8.70%25 3-1 Month Momentum % is -43.59% as of Jul. 23, 2026. GuruFocus rates ASX:DXB with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 1,388 Biotechnology companies, Dimerix ranks worse than 89.41% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-23), Dimerix's 3-1 Month Momentum % is -43.59%.
The industry rank for Dimerix's 3-1 Month Momentum % or its related term are showing as below:
ASX:DXB's 3-1 Month Momentum % is ranked worse than 89.41% of 1388
companies
in the Biotechnology industry
Industry Median: -12.625
vs ASX:DXB: -43.59
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Dimerix 3-1 Month Momentum % Related Terms
ASX:DXB vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Dimerix's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimerix 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dimerix's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Dimerix's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimerix (ASX:DXB) has a 3-1 Month Momentum % of -43.59% as of Jul. 23, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Dimerix and its competitors. According to the industry distribution chart, Dimerix ranks #1241 out of 1388 companies in the Biotechnology industry, placing it in the top 89.4%.
Is Dimerix's 3-1 Month Momentum % too high?
Dimerix's current 3-1 Month Momentum % is -43.59%. Based on the distribution chart, Dimerix ranks #1241 out of 1388 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dimerix has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Dimerix's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dimerix ranks #1241 out of 1388 companies for 3-1 Month Momentum %. This places Dimerix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Dimerix and its competitors. Dimerix's current 3-1 Month Momentum % is -43.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimerix stock overvalued right now?
Dimerix (ASX:DXB) has a current 3-1 Month Momentum % of -43.59%. The current 3-1 Month Momentum % is -43.59%. Dimerix's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Dimerix (ASX:DXB), the current 3-1 Month Momentum % is -43.59% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
25GF Score
Get the complete analysis for ASX:DXB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:DXB has been successfully added to your 
